Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

Key Inclusion Criteria:

   - Histologically or cytologically confirmed metastatic or locally recurrent HNSCC that
   is considered incurable by local therapies

Safety Run-in Cohort 1 and Phase 2 Cohorts 1

   - Should not have had prior systemic therapy administered in the recurrent or metastatic
   setting.

   - Eligible primary tumor locations include oropharynx, oral cavity, hypopharynx, and
   larynx. Nasopharynx is not included.

   - HNSCC per protocol specified inclusion criteria regardless of PD-L1 status

Safety Run-in Cohort 2 and Phase 2 Cohort 3

   - Histologically or cytologically confirmed locally advanced/mHNSCC regardless of PD-L1
   status with at least 1 and no more than 2 lines of prior systemic anticancer therapy
   in the locally advanced/metastatic setting

Key Exclusion Criteria:

   - Active central nervous system (CNS) disease (individuals with asymptomatic and stable,
   treated CNS lesions who have been off corticosteroids, radiation, or other
   CNS-directed therapy for at least 4 weeks are not considered active)

   - History of (noninfectious) pneumonitis that required steroids or current pneumonitis

Safety Run-in Cohort 1, Pre-expansion Safety Run-in Cohort for Magrolimab + Pembrolizumab
(if Applicable), and Phase 2 Cohorts 1 and 2

   - Prior treatment with any of the following:

      - Anti-programmed cell death protein 1 or anti-PD-L1 checkpoint inhibitors

      - Anti-cytotoxic T-lymphocyte-associated protein 4 checkpoint inhibitors

Safety Run-in Cohort 2 and Phase 2 Cohort 3

   - Progressive disease within 6 months of completion of curatively intended systemic
   treatment for locally advanced/mHNSCC

   - Prior treatment with a taxane

Note: Other protocol defined Inclusion/Exclusion criteria may apply.